Wave Life Sciences’ WVE-007 Shows 14% Visceral Fat Reduction, 88% Activin-E Suppression
A single 240 mg dose of WVE-007 drove placebo-adjusted 14% visceral fat reduction (p<0.05), 5% total fat loss, 3% waist circumference decrease and 1% body weight loss at six months. Activin-E suppression up to 88% and a safe profile support once- or twice-yearly dosing in obesity and cardiometabolic indications.
1. Efficacy Results from Phase 1 Trial
In the 240 mg cohort of 32 participants (mean BMI 32 kg/m2), a single dose of WVE-007 achieved placebo-adjusted reductions in visceral fat of 14.3% (p<0.05), total fat loss of 5.3%, waist circumference decline of 3.3% and body weight loss of 0.9%, alongside a 2.4% increase in lean mass at six months.
2. Durability and Safety Profile
WVE-007 demonstrated durable pharmacology, sustaining up to 88% serum Activin E suppression through at least seven months. The therapy was generally safe and well tolerated at doses up to 600 mg, with no severe or serious adverse events and only mild or moderate treatment-emergent effects.
3. Comparison and Next Steps
Visceral fat-to-muscle ratio improved by 16.5% versus 12.2% seen with weekly semaglutide in later-stage trials. Wave Life Sciences plans to initiate the Phase 2a portion of INLIGHT in 2Q 2026 in higher-BMI individuals, with data expected to guide expansion into obesity, MASH, type 2 diabetes and cardiovascular disease indications.